Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy - A critical assessment

Urology

Volumn 53, Issue 4, 1999, Pages 722-730

  Brändle, Edgar ^a   Hautmann, Oliver ^a   Bachem, Max ^a   Kleinschmidt, Klaus ^a   Gottfried, Hans Werner ^a   Grünert, Adolf ^a   Hautmann, Richard E ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN; PROSTATE SPECIFIC ANTIGEN; SERUM ALBUMIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD LEVEL; CLEARANCE; CLINICAL ARTICLE; EXTRAVASCULAR SPACE; HALF LIFE TIME; HEMODILUTION; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY;

EID: 0033119847     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00593-7     Document Type: Article

References (24)

1. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
2. McCormack RT, Rittenhouse HG, Finlay JA, et al: Molecular forms of prostate-specific antigen and the human kallikrein gene faminly: a new era. Urology 54: 729-744, 1995.
3. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate specific antigen to improve specifity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
4. Luderer AA, Chen Y-T, Soriano TE, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
5. Agha AH, Schechter E, Roy JB, et al: Prostate specific antigen is metabolized in the liver. J Urol 155: 379-384, 1996.
6. Richardson TD, Wojno KJ, Liang LW, et al: Half life determination of serum free prostate specific antigen following radical retropubic prostatectomy. Urology 48: 40-44, 1996.
7. Partin AW, Piantadosi S, Subong ENP, et al: Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate Suppl 7: 35-39, 1996.
8. 1-antichymotrypsin from serum. Urology 51: 57-62, 1998.
9. Lein M, Brux B, Jung K, et al: Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy. Eur J Clin Chem Biochem 35: 591-595, 1997.
10. Semjonow A, Hamm M, and Rathert P: Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World J Urol 11: 218-220, 1993.
11. Semjonow A, Hamm M, and Rathert P: Half-life time of prostate-specific antigen after radical prostatectomy: the decisive predictor of curative treatment? Eur Urol 21: 200-205, 1992.
12. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
13. Oesterling JE, Bruzek DJ, Rock RC, et al: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139: 766-772, 1988.
14. Haab F, Meulemans A, Dauge C, et al: Clearance of PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy. Prostate 26: 334-338, 1995.
15. Brändle E, Gottfried HW, Maier S, et al: 1st die radikale Prostatektomie ein geeignetes Modell zur Bestimmung der PSA-Halbwertzeit? Urologe [A] 34: 419-423, 1995.
16. Schroder FH, Hermanek P, Denis L, et al: The TNM classification of prostate cancer. Prostate Suppl 4: 129-138, 1992.
17. Woodrum D, French C, and Shamel LB: Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 48: 33-39, 1996.
18. Gibaldi M, and Pemen D: Method of residuals, in Gibaldi M, and Pemen D (Eds): Pharmacokinetics. New York, Marcel Dekker, 1975, pp 281-292.
19. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2C or lower) prostate cancer. J Urol 152: 1850-1857, 1994.
20. Smeets HJ, Kievit J, Dulfer FT, et al: Analysis of postoperative hypalbuminaemia: a clinical study. Int Surg 79: 152-157, 1994.
21. Taggart DP, Fraser WD, Fell GS, et al: Plasma albumin and haemodilution: the problem of interpretation in sequential studies. Ann Clin Biochem 26: 132-136, 1989.
22. Kirsch R, Frith L, Black E, et al: Regulation of albumin synthesis and catabolism by alteration of dietary protein. Nature 217: 578-579, 1968.
23. Rothschild MA, Oratz M, and Schreiber SS: Albumin synthesis, in Rosenooerv VM, Oratz M, and Rothschild MA (Eds): Albumin Structure, Function and Uses. Oxford, Pergamon Press, 1977, pp 227-253.
24. Gladtke E, and von Hattingberg HM: Pharmakokinetik. Berlin, Springer Verlag, 1977, pp 49-52.